Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).

Matthew S. Davids,John F. Seymour,John F. Gerecitano,Brad S. Kahl,John M. Pagel,William G. Wierda,Mary Ann Anderson,David E. Darden,Cathy E. Nolan,Lori A. Gressick,Jianning Yang,Brenda Chyla,Todd A. Busman,Alison M. Graham,Elisa Cerri,Sari H. Enschede,Rod A. Humerickhouse,Andrew W. Roberts

Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).

2017

Matthew S. Davids
John F. Seymour
John F. Gerecitano
Brad S. Kahl
John M. Pagel
William G. Wierda
Mary Ann Anderson
David E. Darden
Cathy E. Nolan
Lori A. Gressick
Jianning Yang
Brenda Chyla
Todd A. Busman
Alison M. Graham
Elisa Cerri
Sari H. Enschede
Rod A. Humerickhouse
Andrew W. Roberts

8520 Background: BCL-2 is highly expressed in NHL, including mantle cell lymphoma (MCL), and is a promising therapeutic target as it is involved in NHL pathogenesis and mediates resistance to many ...

Keywords:

Pathology
Refractory Non-Hodgkin Lymphoma
Pathogenesis
Cancer research
Bcl-2 Inhibitor
Medicine
Mantle cell lymphoma
Human study
first in human
hodgkin lymphoma
in patient
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations